WEED, Inc. (OTC:BUDZ) to Present its $40 Million RegA+ Offering at Starlight Capital’s Investment & Technology Conference tomorrow March 25th, 2021
Press Release | 03/24/2021
TUCSON, AZ / ACCESSWIRE / March 24, 2021 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company"), one of the top cannabis and hemp bioresearch companies based in the USA, announced today that WEED Chief Executive Officer Glenn E. Martin will present at Starlight Capital's virtual conference tomorrow, March 25th between 12 noon and 2PM EDT. Martin will announce WEED's opportunities to invest in a new $40M financing round in BUDZ under Regulation A, Tier 2 as recently qualified by the Securities and Exchange Commission (See WEED, Inc. Offering pitchdeck Here.)
Thanks to the Company's extensive R&D history in cannabis and hemp markets, WEED is on the verge of a major expansion. Martin will describe the Company's history and its current and targeted real estate and IP assets and other opportunities as well as the Company's plans post-COVID. The Company is pleased to announce its new program to expand its global research & development program, which currently includes WEED Inc. subsidiaries and partners in Australia, Israel, Hong Kong, and the USA. At the same time, the Company will launch an aggressive program to identify, acquire, and integrate domestic and foreign assets and businesses that will most directly benefit from the continued opening up of cannabis markets worldwide - principally, retail and wholesale producers of cannabis and hemp plants and their derivative products.
"All indications are that there may never be a better time to go ‘all-in' on the future of Cannabis and Hemp markets, and we want the public to join us," said Glenn E. Martin, CEO of WEED, Inc. "We created this Reg A+ offering so that all investors - not just the big, accredited guys - can be part of the growth and expansion we expect for 2021 and beyond. This is where stoners Meet Wall Street."
Investors may sign up at no charge here: https://www.starlightcapital.co/event-info/starlight-capital-technology-investment-forum
WEED, Inc.'s Subsidiaries
WEED Israel (Cannabis) Ltd. "After over a year of putting human clinical trials and product development on hold due to COVID, Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich our lives for generations to come."
WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik commented, "With the new rules just out governing cannabis in Australia and the announcement on 1st. February 2021 to allow over-the-counter CBD medicines in pharmacies, WEED Australia congratulates USA's new administration of President Joe Biden and its historic vote for Vice President Kamala Harris." Managing Director Brodnik continues, "We expect the future of decriminalizing cannabis and hemp in the USA to prove to be a giant leap forward for global cannabis legalization."
WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come."
WEED, Inc., a Nevada corporation (the Company, WEED, we, or our) is offering (the "Offering") up to a maximum of 40,000,000 units ("Units"), with each Unit consisting of one (1) share of our common stock, par value $0.001 ("Common Stock") and one (1) warrant to purchase (1) share of our common stock, at a purchase price of $1.00 per Unit. The exercise price on the warrant will be 150% of the price of the Unit sold to the investor and cannot be exercised by the holder until at least twelve months after issuance.
The Units are being offered pursuant to Regulation A of Section 3(b) of the Securities, as amended, for Tier 2 offerings, by management on a "best-efforts" basis directly to purchasers who satisfy the requirements set forth in Regulation A.
Securities are offered and distributed pursuant to Regulation A+ through Dalmore Group LLC, a registered broker dealer, member FINRA (www.FINRA.org) and member SIPC (www.SIPC.org). These securities being offered are highly speculative due to the nature of the investment, and the fact that cannabis remains a controlled substance at the Federal level according to Schedule 1 of the Controlled Substances Act of 1970.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Legal Notice
This press release is for information purposes only and does not constitute an offer or sale of the securities referenced herein. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A, Tier 2 of the Securities Act of 1933. A link to the qualified offering circular and related offering documents is attached hereto and all prospective investors should carefully review these materials, which includes important disclosures and risk factors associated with an investment in WEED, Inc. These securities have not been recommended by the Securities and Exchange Commission or any state securities commission or regulatory authority, nor has any commission or regulatory confirmed the accuracy of the information contained the offering materials.
The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.
Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com
Investor Contact:
Bryan Emerson
Great Point Capital
200 W. Jackson Blvd., Ste 1000
Chicago, IL 60606
bemerson@gpcchi.com
First Apex International
Scott Biddick, Managing Director
Investors@WEEDincUSA.com
WEED, Inc. Launches $40 Million Offering To Fuel Expansion, Acquisitions
Press Release | 02/24/2021
TUCSON, AZ / ACCESSWIRE / February 24, 2021 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company"), one of the top cannabis and hemp bioresearch companies in the USA, announced today the launch of a new $40M financing round under Regulation A, Tier 2 as recently qualified by the Securities and Exchange Commission (See WEED, Inc. Offering Circular Here.)
Thanks to the Company's extensive R&D history and the current state of worldwide politics and public opinion, WEED's management believes the cannabis and hemp markets are ready for another wave of expansion and growth. The Company is pleased to announce its new program to expand its global research & development program, which currently includes WEED Inc. subsidiaries in Australia, Israel, Hong Kong, and the USA. At the same time, the Company will launch an aggressive program to identify, acquire, and integrate domestic and foreign assets and businesses that will most directly benefit from the continued opening up of cannabis markets worldwide - principally, retail and wholesale producers of cannabis and hemp plants and their derivative products.
"All indications are that the Cannabis and Hemp markets have momentum and we want to give the opportunity for the public to join us," said Glenn E. Martin, CEO of WEED, Inc. "We created this Reg A+ offering so that all investors - not just the big, accredited guys - can be part of the growth and expansion we expect for 2021 and beyond. It's where stoners meet Wall Street."
WEED, Inc.'s Subsidiaries
WEED Israel (Cannabis) Ltd. "After over a year of putting human clinical trials and product development on hold due to COVID, WEED Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich our lives for generations to come."
WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik commented, "With the new rules just out governing cannabis in Australia and the announcement on 1st. February 2021 to allow over-the-counter CBD medicines in pharmacies, WEED Australia is excited for the future, and we congratulate the USA's new administration of President Joe Biden and its historic vote for Vice President Kamala Harris." Managing Director Brodnik continues, "The future of decriminalizing cannabis and hemp in the USA shall prove to be a giant leap forward for global cannabis legalization."
WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come."
WEED, Inc., a Nevada corporation (the Company, WEED, we, or our) is offering (the "Offering") up to a maximum of 40,000,000 units ("Units"), with each Unit consisting of one (1) share of our common stock, par value $0.001 ("Common Stock") and one (1) warrant to purchase (1) share of our common stock, at a purchase price of $1.00 per Unit. The exercise price on the warrant will be 150% of the price of the Unit sold to the investor and cannot be exercised by the holder until at least twelve months after issuance.
The Units are being offered pursuant to Regulation A of Section 3(b) of the Securities Act of 1933, as amended, for Tier 2 offerings, by management on a "best-efforts" basis directly to purchasers who satisfy the requirements set forth in Regulation A.
Securities are offered and distributed pursuant to Regulation A+ through Dalmore Group LLC, a registered broker dealer, member FINRA (www.FINRA.org) and member SIPC (www.SIPC.org). These securities being offered are highly speculative due to the nature of the investment, and the fact that cannabis remains a controlled substance at the Federal level according to Schedule 1 of the Controlled Substances Act of 1970.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Legal Notice
This press release is for information purposes only and does not constitute an offer or sale of the securities referenced herein. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A, Tier 2 of the Securities Act of 1933. A link to the qualified offering circular and related offering documents is attached hereto and all prospective investors should carefully review these materials, which includes important disclosures and risk factors associated with an investment in WEED, Inc. These securities have not been recommended by the Securities and Exchange Commission or any state securities commission or regulatory authority, nor has any commission or regulatory authority confirmed the accuracy of the information contained in the offering materials.
The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.
Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com
Investor Contact:
First Apex International
Investors@WEEDincUSA.com
SOURCE: WEED, Inc.
WEED Inc. 'SALUTES' our Veterans & Arizona's Historic VOTE
Press Release | 11/11/2020
Congratulations: New Jersey, Montana, South Dakota & Mississippi
Fully legal in 15 States , "ALL Fifty States in 50 Months" #LegalizeNow
TUCSON, AZ / ACCESSWIRE / November 11, 2020 / WEED, Inc. (OTCQB:BUDZ), the holding company focused on the development and application of cannabis-derived compounds for the treatment of human diseases has continued its pursuit of developing and acquiring intellectual property and trademark rights, along with product development strategies for both domestic and global markets.
"After 50+ years of advocacy, I've lived to see legalization for Natures Healing Plant Cannabis in all its forms" declares WEED's CEO Glenn E. Martin. "With the recent election results, I believe Arizona will be brought to the forefront for potential new therapies, treatments and eventual cures for many diseases, both man & beast, utilizing ‘next' generation cannabis genetics and medical cannabis breakthroughs" Martin continues, "Our veterans served & died for our Freedom, to use cannabis and other natural medicines. Now its Americas time to Honor our VETS with full legalization."
!BEARDOWN AZ - CONGRATULATIONS!
WEED 2020 updates:
Nicole Breen WEED's Sec/Treas. commented; "WEED, Inc. filed for a Regulation A+ offering with S.E.C. on February 11th, 2020 and is anxious to begin its offering, hopefully in the near future . Due to the current pandemic, WEED's national/International projects, studies and Doctors Education programs are currently on hold. I wish to assure our shareholders that we have kept current with all obligations, no personnel have been laid off or terminated". Mrs. Breen continued, "Everyone's safety & security is our utmost concern and priority in making decisions moving forward with product development and international expansion." WEED's management also announced the following additional updates:
2 previously filed litigations in Colorado & Arizona have been successfully defended with both suits being terminated to the benefit of WEED Inc shareholders. There is no current or pending litigation.
WEED's acquisition of the Sugar Hill Golf course in Western New York is on schedule to close Feb 1st. 2021, assuming WEED raises the additional funds for the closing. WEED looks to eventually utilize the property to develop an infused beverages & edibles research division, with hemp/cannabis products planned for the NY marketplace & beyond.
WEED Australia Ltd. has completed its 2017 & 2018 audits from KPMG Australia. This important milestone, as a regulated ASIC company, are essential in moving forward with planned public offerings in 2021. (Fiscal year ends June 30) Year 2019 & 2020 audits are underway. Wildfires & Covid-19 have slowed the process due to restricted air travel.
About WEED Australia Ltd. and The Cannabis Institute of Australia
WEED Australia Ltd.'s corporate strategy is to become a leader in cannabis/hemp research and product development. To support this goal WEED Australia Ltd. has assembled a highly qualified team of well-respected Ph.D.'s, scientists, researchers and business experts with the goal of establishing domestic use and export industries for Australians.
About WEED Israel (Cannabis) Ltd.
WEED Israel Cannabis Ltd. looks to complete Patent & Trademark acquisitions, start human clinical trials once Covid-19 is defeated and WEED Israel can start-up safely again to develop both Pharmaceutical & non-pharmaceutical products for domestic use and International exports.
WEED Israel Cannabis Ltd. was established to build and expand WEED, Inc.'s global presence. In support of WEED Israel Cannabis Ltd., WEED, Inc. had entered into an exclusive license and assignment agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Israel. The agreement was for five patents, technology and know-how relating to formulations for the administration and delivery of cannabinoid compounds has been terminated. These patents were developed by Prof. Elka Touitou at the Hebrew University of Jerusalem and will be reviewed once over Covid-19 pandemic & Israeli regulations are clarified.
About Sangre AT, LLC dba Sangre BioSciences.
Sangre AT, LLC (dba "Sangre BioSciences"), WEED, Inc.'s wholly owned US subsidiary, is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre BioSciences, please visit www.WEEDincUSA.com
About WEED Hong Kong Limited:
WEED Hong Kong Limited was established April 23rd, 2019 as an International subsidiary of WEED Inc USA. A special purpose holding company for development of our Patents, Trademarks, Copyrights and intellectual Property for company and brands of WEED Inc. on a global basis. Glenn E Martin, Director, President, CEO. Nicole Marie Breen, Director and company Treasurer. Ed Lehman, of Lehman, Le and Xu Corporate Services Limited, is appointed the corporate secretary. Registered office: Lehman, Lee and Xu. Suite 3313, Tower One, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong. WEED Hong Kong Limited, has maintained its corporate presence but kept dormant due to Covid-19 pandemic.
About WEED, Inc.
WEED, Inc. (BUDZ) is currently a USA-based fully reporting public company, quoted on the OTCMarkets. (OTCMarkets.com) WEED Inc. is a multi-national, multi-faceted, vertically integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brands.
WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED Inc, please visit: www.WEEDIncUSA.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, here or abroad, nor shall there be any sale of the shares of common stock in any state or country in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process, along with control of the global Covid-19 pandemic.
For more information, contact:
Glenn E. Martin
(520) 818-8582
info@WEEDIncUSA.com
SOURCE: WEED, Inc.
The advent of adult legal use of Cannabis has caused an explosion of innovation. The rate at which new products being offered in this space is occurring is somewhat unprecedented and isn’t likely to stop anytime soon. As the pace of this modernization and the scale of Cannabis and Hemp cultivation operations continues to grow, the costs associated with production will fall. The expectation is that this will lead to higher margins and greater
profitability for the industry overall.
It’s hard to predict what the growth of the Cannabis and Hemp industries will be, as so much of its future is tied to changes in legality. The one consistent prediction, however, is that growth is coming. Whenever another US state or another country opens up the possibility for legal Cannabis use, it increases the opportunities and changes the landscape.
Cannabis and Hemp cultivation, processing, medical applications, and related products for both human and animals are now becoming the wave of the future. A future in which Cannabis and Hemp are a mainstream industry
which could eclipse other related products, such as beer, wine and tobacco
and any number of medical applications and treatments.
There is a broad global interest in investment in this emerging space. With the legalization of adult use, Cannabis coming to pass in Canada, the possibility that something similar could come to pass in the US, Australia,
and the rest of the world seems easier to believe than ever before.
For those with the imagination to see where this road could lead, and the willingness to take a chance, the potential for returns could be substantial. Make no mistake though, and Cannabis is moving out of the smoky back
rooms and is no longer something to laugh about. It is becoming a significant business budding with possibilities.
Even though the global Cannabis market is still in its infancy, many investment experts are making bold predictions about where it could be headed, such as The Green Fund’s Mark Bernberg who wrote recently “We believe that the largest cannabis company in the world doesn’t even exist yet.”
Cannabis is one of the fastest growing industries in the world. As the liberalization of Cannabis laws continues, and access to medicinal products derived from Cannabis increases the value of medical cannabis institutions and products are expected to increase accordingly. Some estimates predict that the value of the North American Cannabis market will reach 146.4 billion dollars by the end of 2025 (1). A significant contributor to that forecasted growth is the increased use of Cannabis derived medicines and treatments for a broader range of ailments and conditions than it is currently being used to care for.
Due to recent regulatory changes medical professionals, researchers, and scientists will have more opportunities to study the effects of Cannabinoid compounds. This will likely lead to the discovery of better and more varied ways to employ Cannabis as a medicine.
In a related development, on March 20th of this year, Mr. Glenn E. Martin, CEO of WEED, Inc. announced that WEED, Inc., and Yissum (of the Hebrew University of Jerusalem) signed first-of-its-kind deal for exclusive license, assignment and transfer to WEED Inc. of groundbreaking intellectual property for novel technologies and formulations of cannabis-related and cannabinoid-based products for the treatment of medical disorders and
conditions.
WEED Inc. in the same press release also announced that it has entered into a consulting agreement with Prof. Elka Touitou, of the Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem.
Prof. Touitou is a pioneer in cannabinoid research and published the firsts scientific work on transdermal delivery of cannabinoids in 1988. Prof. Touitou and WEED, Inc. are looking to develop efficient products focused on
woman's health, utilizing Cannabinoids.
